D
David Zhuo
Researcher at University of Pennsylvania
Publications - 4
Citations - 1420
David Zhuo is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Chromatin immunoprecipitation & Peroxisome proliferator-activated receptor. The author has an hindex of 4, co-authored 4 publications receiving 1292 citations.
Papers
More filters
Journal ArticleDOI
PPARγ and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale
Martina I. Lefterova,Yong Zhang,David J. Steger,Michael Schupp,Jonathan Schug,Ana G. Cristancho,Dan Feng,David Zhuo,Christian J. Stoeckert,X. Shirley Liu,Mitchell A. Lazar +10 more
TL;DR: Peroxisome proliferator-activated receptor gamma (PPARgamma), a nuclear receptor and the target of anti-diabetic thiazolinedione drugs, and C/EBPbeta also plays a role at many of these genes, such that both C/EBPalpha and beta are required along with PPARGamma for robust adipocyte-specific gene expression.
Journal ArticleDOI
DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells.
David J. Steger,Martina I. Lefterova,Lei Ying,Aaron J. Stonestrom,Michael Schupp,David Zhuo,Adam L. Vakoc,Ja Eun Kim,Junjie Chen,Mitchell A. Lazar,Gerd A. Blobel,Christopher R. Vakoc +11 more
TL;DR: It is reported that DOT1L recruitment is ubiquitously coupled with active transcription in diverse mammalian cell types and highlighted several similarities between the patterning of H3K4 methylation and that of H2K79 methylation in mammalian chromatin, suggesting a widespread mechanism for parallel or sequential recruitment of DOT1l and MLL to genes in their normal “on” state.
Journal ArticleDOI
Cell-Specific Determinants of Peroxisome Proliferator-Activated Receptor γ Function in Adipocytes and Macrophages
Martina I. Lefterova,David J. Steger,David Zhuo,Mohammed Qatanani,Shannon E. Mullican,Geetu Tuteja,Elisabetta Manduchi,Gregory R. Grant,Mitchell A. Lazar +8 more
TL;DR: The nuclear receptor peroxisome proliferator activator receptor γ (PPARγ) is the target of antidiabetic thiazolidinedione drugs, which improve insulin resistance but have side effects that limit widespread use.